SHORT REPORTS
Macrocytic anaemia in patients treated with sulphasalazine for rheumatoid arthritis Sulphasalazine is a "disease modifying" drug that is now widely used in rheumatoid arthritis, having fewer and milder side effects than gold or penicillamine.' One potential side effect, which is easily missed and may become life threatening, is macrocytic anaemia. This occurs in 2-3% of prising and possibly to "reflect the brittle state of folate metabolism in rheumatoid arthritis." Since then the development of macrocytic anaemia during treatment with sulphasalazine has been mentioned in reports but has drawn little attention. Recently it was suggested that sulphasalazine does not cause folate deficiency in rheumatoid arthritis at a dose below 2 g/day,5 but the number of patients and duration of the study do not allow a definite conclusion to be reached. Certainly, folic acid deficiency is more likely to occur when additional causes of it are present and when sulphasalazine is given in higher dosage. It is an important complication as it is potentially serious, easily treated, and not an indication for stopping sulphasalazine. patients with inflammatory bowel disease treated with sulphasalazine. We have found it in seven of 50 patients with rheumatoid arthritis treated with sulphasalazine, one of whom had pancytopenia.
Case reports Ofthe 50 patients with progressive erosive rheumatoid arthritis who were given sulphasalazine, seven developed macrocytic anaemia within three to four months (table). None had previously had macrocytic anaemia, and no predictive factors were evident, although one patient had coeliac disease, which was being treated. Folate deficiency was found in all seven cases: low serum vitamin B12 concentrations were also found in three cases, but they did not respond to injections of vitamin B12. All patients responded to supplementation with folic acid and restarted sulphasalazine without problems while taking such supplements.
Case 1-The most severely affected patient was a 69 year old man, who started sulphasalazine at 1-5 g/day, increasing to 3 g/day one month later. He had a good subjective and objective response for three months without any problems, but a chronic gastric ulcer recurred, necessitating admission to hospital and repeated endoscopy. A reduction in haemoglobin concentration from 114 to 73 g/l was attributed to the ulcer, and he continued taking sulphasalazine with treatment for his ulcer. He was readmitted two months later with pancytopenia, having defaulted from follow up. Investigation showed: haemoglobin concentration 36 g/l, mean cell volume 129 fl, white cell count 3 5xlO9/lf, platelet count 30x 109/l; megaloblastic bone marrow; red cell folate concentration 127 ng/ml; and serum vitamin B12 concentration 50 mg/l. A Schilling test showed normal absorption of vitamin B12, and there was no response to injected vitamin B12. Reticulocytosis occurred during treatment with oral folic acid and the pancytopenia resolved.
Comment
The overall incidence of unwanted side effects to sulphasalazine may be similar in inflammatory bowel disease and rheumatoid arthritis. Two recent reviews found that 28 of 133 patients (21%) with inflammatory bowel disease and 46 of 158 patients (29%) with rheumatoid arthritis developed an adverse reaction.2 3 Macrocytic anaemia, however, may be more common in patients with rheumatoid arthritis. important difference with goserelin is that the ease and convenience of its administration should radically improve compliance and greatly decrease the logistic complexity of studies using these compounds. The effect of the drug means that a monthly injection will suffice to maintain constant pituitary suppression. We have shown resumption ofovarian cyclicity after a single injection where the resultant luteal phases appeared both qualitatively and quantitatively normal. This normality implies normal folliculogenesis and reduces anxiety about the use of the drug in infertile women. These Convrsion:SI to tradizionalw -Oestradiol: lpmol/10'28 pg/mi. Progesterone-1 pmolV0 31 pg/ml.
The patients were aged 38 to 41 years. The subcutaneous injection into the antenor abdominal wall was simple and virtually painless. There were no local or systemic reactions. Apart from slight vaginal spotting in three patients, amenorrhoea resulted which lasted between 61 and 71 days. All the patients experienced hot flushes but in only two did these occur more than three times a day and in none were they severe. There were no other symptoms of oestrogen withdrawal or other side effects. The vaginal bleeding aft amenorrhoea was similar in type, quaity, and durtion -to normal menstruaion.
The figure shows the plasma luteinising-h6rmone and oestmdiolconcentrations throughout treatment. The figure also shows the salivary progesterone concentratons in the 15 days before the onset of menstruation. Theimean concenion exceeded 300 pmol/ (93 pg/mn) from day -10 to day -2. This cois dered to be the minimum seen during the normal mid-luteal phase.5
The study verifies that a single injection of gosrelin depot will suppress luteinising hormone secretion for roughly five weeks. This phenomenon is common to other luteinising hormone releasing hormone agonists, but the observations should make it simpler to instigate studies investigating the important applications for the compound iii polycystic ovary syndrome, premature ovarian failure, and endometriosis. 
